Pharmaceutical Investing Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts
Pharmaceutical Investing PADCEV Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Pharmaceutical Investing Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
Pharmaceutical Investing Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
Pharmaceutical Investing TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
Pharmaceutical Investing Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma
Pharmaceutical Investing Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance
Pharmaceutical Investing Arvinas Announces Data Presentations from the Vepdegestrant Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium
Pharmaceutical Investing U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
Pharmaceutical Investing Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance
Pharmaceutical Investing Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition
Goldgroup Enters Into Agreement To Sell Subsidiary Minera Apolo, S.A. de C.V., Disposing of Pinos Project
